drugset / Trial / NCT03393416
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
NaSingle-groupOpen-labelTreatment
Summary
This study evaluate the safety and tolerance of MASCT-I(multiple-antigen specific cell therapy) combined with PD1 antibody in patients with advanced gastric cancer who failed in first-line chemotherapy. The study is divided into three stages: the first, second stage is the stage of the dose climbing, and the third stage is the dose expansion stage. The patients would be treated with MASCT-I single drug therapy, MASCT-I+ low dose PD1 antibody therapy, and MASCT-I+ high dose PD1 antibody therapy.
Timeline
- Start
- 2018-04-19
- Primary completion
- 2020-07
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MASCT-I | Cell therapy | — | — |
| Subject | Sintilimab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Sintilimab | Monoclonal antibody | 3 mg/kg | — |